Clinical Trials
15 trialsNCT03226704 2026-05-20
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
National Institutes of Health Clinical Center (CC)
Enrolling by invitation
NCT06784726 2026-05-06
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT07042438 2026-03-05
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
Phase 2 Recruiting
NCT06191887 2026-02-13
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT06834373 2026-01-28
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
Phase 2 Recruiting
NCT07098364 2026-01-14
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting
NCT02570542 2025-11-26
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06343376 2025-08-03
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Phase 1 Terminated
NCT03103971 2024-04-10
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT02431988 2023-04-28
COBALT
University College, London
Phase 1 Completed
NCT01408043 2019-06-14
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase NA Terminated
NCT00566228 2018-07-09
Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma
Mayo Clinic
Phase 3 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed